Вы находитесь на странице: 1из 24

I.

Pathophysiology of Heart Failure


a. Frank Starling Mechanism
i. “The more I get, the more I pump.”
ii. Fiber stretch depends on preload.
iii. Amount of stretch determines force.
iv. Normal: Inc Preload -> Inc SV
v. Failure: Inc Preload -> Dec SV
b. Types of Heart Failure
i. HFpEF – Preserved Ejection Fraction
1. Diastolic HF
2. LVEF ≥50%
ii. HFrEF – Reduced Ejection Fraction
1. Systolic HF
2. LVEF ≤40%
iii. HFpEF, borderline: 41-49%
iv. HFpEF, improved: > 40%
c. Compensation
i. Neurohormones
1. Angiotensin II – ATII
a. Vasoconstriction
b. NE & Aldosterone Release
c. Ventricular Hypertrophy (VH)
d. Cardiac Remodeling (CaR)
e. Increases Preload
f. Increases Afterload
2. Norepinephrine – NE
a. Vasoconstriction
b. Tachycardia
c. Contractility
d. Down regulates beta receptors
e. VH
f. CaR
g. Pro-arrythmic
h. Increases Afterload
3. Aldosterone
a. Na & H2O Retention
i. Increased fluid volume
b. Production of cardiac fibrosis
c. Pro-arrythmic
d. Increases Preload
4. Brain Natriuretic Peptide – BNP
a. Elevated in ventricular injury (MI)
b. Natriuresis (Na)
c. Diuresis
d. Vasodilation
e. Lowers Preload
5. Endothelin-1 – ET-1
a. Vasoconstrictor
b. Decreases renal blood flow
c. VH
d. Pro-arrythmic
e. Positive inotrope (force)
6. Neprilysin
a. Neutral endopeptidase
b. Degrades BNP
ii. Mechanisms
1. Tachycardia & Increased Contractility
a. NE – SNS Activation
i. Increased intracellular Ca -> Increased
Contractility
ii. Increased HR -> Decreased Lusitropy
(ventricular relaxation) -> Increased O2
demand
iii. Vasocontriction can preserve blood supply
2. Fluid Retention & Increased Preload
a. Kidneys detect low perfusion -> Renin Released
b. Renin Cleaves angiotensinogen to AT1
c. AT1 + ACE -> ATII
i. NE & Aldosterone Release
3. Vasoconstriction & Increased Afterload
a. Reduced CO -> Blood Redistribution
b. Vasoconstriction -> Decreased EF
i. Decreased EF -> Increased Afterload
c. NE, ATII, ET-1
4. Ventricular Hypertrophy & Cardiac Remodeling
a. CaR -> VH
i. Myocardium walls thicken
ii. Ellipse -> Sphere
b. Less volume to fill with blood
c. NE, ATII, ET-1, Vasopressin, cytokines
iii. Symptoms
1. Dyspnea (esp. on exertion)
a. Pulmonary congestion
2. Peripheral edema
a. Increased Preload -> Less Venous Return
3. Fatigue/weakness/lethargy
4. Orthopnea (pillow orthopnea)
5. SOB
6. Paroxysmal nocturnal dyspnea
7. Exercise intolerance
8. Tachypnea
9. Cough
10.Nocturia/Polyuria
11.Bloating
12.Mental Status Changes
iv. Signs
1. Rales or crackles at lower lung base
a. SOB, cough, dyspnea
b. Pulmonary congestion
2. Tachycardia
a. NE -> palpitations
3. Hypotension (postural)
a. Low CO -> Poor compensation for position change
4. JVD – Jugular Venous Distention
a. Fluid Overload
5. Lab Parameters
a. BNP or NT-proBNP
i. BNP > 100 pg/mL or NT-proBNP > 300
pg/mL
1. Consider LV dysfunction
ii. Non-specific can be elevated in other
conditions
b. CBC for O2 carrying capacity
c. CMP
i. Na
1. Volume Overload -> Hyponatremia
ii. K goal > 4 mEq/L
d. Renal & hepatic function
i. Reduced Renal Perfusion -> Increased
Creatinine
e. Baseline
i. Urinalysis, lipid, Glu/A1C, thyroid
v. Staging/Classification
1. ACCF/AHA – Evaluates HF Progression
a. A-D
i. High Risk -> Severe HF Symptoms
2. NYHA – Classifies symptoms
a. I-IV
i. No Physical Limitation -> Unable to Carry
Out Any Physical Activity
II. Cardiac Stimulants & Inotropes: Pharmacology
a. Positive Inotropes: Stronger Force of Contraction
i. Digitalis glycoside
1. Digoxin: Na/K/ATPase Inhibitor
a. Steroid nucleus, lactone ring, three sugar residues
linked by glycosidic bonds
b. T1/2 = 36 h
i. Renal excretion of parent
c. Positive Inotrope, Negative Chronotrope
d. Negative dromotrope
i. Decrease K -> Decrease Conduction Velocity
e. Increases intracellular Ca & Decreases K
f. Adverse Effects
i. Shortens ST duration
1. Premature ventricular contractions
ii. Anorexia, NV
iii. Halos around objects, yellow/green color
aberrations, blurred vision
iv. Quinidine reduces clearance
g. Digoxin immune Fab: Digoxin Antidote
i. Sheep IG
ii. Adrenoreceptor agonist
1. Dobutamine: beta-1 (in heart) and beta-2 (in vascular
smooth muscle) agonist
a. Catecholamine related to dopamine
b. T1/2 = 2 min
c. Used for cardiac stim during surgery, acute heart
failure, cardio shock
d. Reduces vascular resistance -> Reduced Afterload
-> Increased CO
e. Less tachycardia than other beta agonists
f. Increase cAMP by stimulating adenylate cyclase
i. Increase cAMP -> Activate PKA -> Increase i-
Ca
iii. PDE-3 Inhibitor
1. Milrinone
a. PDE-3 inactivates cAMP -> AMP
b. Increase cAMP -> Activate PKA -> Increase i-Ca
i. Heart: inotropic
ii. Vascular smooth muscle: vasodilation
c. Infants & Children
d. Inamrinone was prototype
III. Heart Failure Therapeutics
a. Types of HF
i. HFpEF – HF with Preserved Ejection Fraction
1. LVEF ≥50%
2. “diastolic HF”
3. Relaxation and filling impaired
ii. HFrEF – HF with Reduced Ejection Fraction
1. LCEF ≤40%
2. “systolic HF”
3. Ventricle too weak -> poor perfusion
b. FACES – Symptom Mnemonic
i. Fatigue
ii. Activity Limitation
iii. Chest Congestion
iv. Edema or ankle swelling
v. Shortness of Breath
c. Outcomes/Goals
i. Reduce morbidity
1. Reduce/relieve symptoms
2. Improve QOL
ii. Prevent or minimize hospitalizations
iii. Slow progression
iv. Reduce Mortality
1. Prolong survival
d. Agents
i. ACEi
1. All HFrEF patients unless CI
2. Reduces ATII -> Reduces aldosterone -> Reduces Preload
3. Lowers BP -> Reduces Afterload
4. Reduces CaR
5. Increase bradykinin -> vasodilation -> decreases
afterload + cough
6. Adverse Effects
a. Hyperkalemia
b. Angioedema
c. Cough
7. Contraindications
a. Pregnancy
b. SCr > 3.0 mg/dL
c. History of AEs
8. Monitor
a. BUN, SCr, K, BP
9. Outcomes
a. Survival
b. Hospitalizations
c. Progression
d. Reinfarction
10. Target Doses
a. Captopril 50 mg TID
b. Enalapril 10-20 mg BID
c. Lisinopril 20-40 mg QD
d. Ramipril 10 mg QD
ii. ARB
1. All HFrEF patients unless CI
2. Can be used after ACE escape or ACE cough
3. AEs & CI same as ACEi
4. Monitor
a. BUN, SCr, K, BP
5. Outcomes
a. Survival
b. Hospitalization
c. Progression
6. Target Dose
a. Valsartan 160 mg BID
b. Candeartan 32 mg QD
c. Losartan 50-150 mg QD
iii. Beta Blocker
1. All HFrEF patients unless CI
2. Beta-1 antagonism -> Reduce HR and BP
a. Decreases load on heart
b. Increase filling -> increase CO
c. Blocks effects of NE
d. Short term: negative inotrope during titration
e. Long term: improved contractility >3 months
3. Adverse Events
a. Fatigue
b. Depression
c. Bradycardia (D-D)
d. Hypotension (D-D)
4. Contraindications
a. Unstable/decompensated HF
b. HR < 60 bpm
c. SBP < 80 mm Hg
d. Sick sinus syndrome
e. 2nd or 3rd degree AV block
5. Monitor
a. BP, HR, signs of congestion
6. Outcomes
a. Survival
b. Hospitalization
c. progression
7. Target Dose
a. Carvedilol IR 25 mg BID < 85 kg, 50 mg BID > 85 kg
with food
b. Carvedilol CR 80 mg QD with food
c. Metoprolol succinate 200 mg QD
i. Tartrate not shown to improve outcomes
d. Bisoprolol 10 mg QD
iv. MRA
1. HFrEF with symptoms
a. NYHA II-IV with EF ≤35%
b. Acute MI with EF ≤40% with symptoms or
diabetes (eplerenone preferred)
2. Adverse Effects
a. Gynecomastia – spironolactone
b. Hyperkalemia
c. Hyponatremia
3. Contraindications
a. ACE + ARB concurrently with MRA
b. K < 5.0 mEq/L
c. SCr ≤2.5 in men or 2.0 in women
d. Spironolactone
i. Anuria
ii. HyperK
iii. CrCl < 10 mL/min
e. Eplerenone
i. CrCl < 30 mL/min
ii. CrCl 50 mL/min with increased SCr
iii. T2DM with microalbuminuria
4. Monitor
a. BUN, SCr, K
5. Outcomes
a. Survival
b. Progression
c. Symptoms
d. hospitalizations
6. Target Dose
a. Spironolactone 50 mg QD
i. Renal dose
b. Eplerenone 50 mg QD
v. Hydralazine/nitrate
1. Black, HFrEF, symptoms despite optimized doses
a. Also symptomatic HFrEF who cannot tolerate
ACE/ARB
2. Nitrate -> venodilation -> reduces Preload
3. Hydralazine -> arterial dilation -> Reduces Afterload
4. Adverse Effects
a. Hypotension
b. Headache (nitrate effect)
5. Monitor
a. BP, HR
6. Outcomes
a. Mortality
b. Hospitalizations
c. QOL
d. Progression
7. Target Doses
a. Bidil – hydralazine 37.5/ISDN 20 mg two tablets
TID
b. Hydralazine 300 mg daily total, divided
c. ISDN 120 mg daily total, divided
vi. Ivabradine
1. HFrEF, symptomatic at optimized beta blocker dose
a. EF ≤ 35%
b. HR > 70 bpm
c. Optimized beta blocker dose
d. Persistent symptoms
2. Reduces HR
3. Maintains contractility
4. Adverse Effects
a. Bradycardia
b. Hypertension
c. Afib
d. Luminous visual phenomena
5. Contraindications
a. Pregnancy
b. BP < 90/50 mm Hg
c. HR < 60 bpm
d. AV/SA block
e. CYP3A4 inhibitors
f. Liver impairment
6. Outcomes
a. Hospitalization (SHIFT trial)
7. Target Dose
a. Ivabradine (Corlanor) 7.5 mg BID
vii. ARNI – Sacubitril/valsartan
1. HFrEF, symptomatic, can tolerate ACEi/ARB
2. Sacubitril – Neprilysin inhibitor
a. Increases BNP -> vasodilation, natriuresis, diuresis
b. Decreases sympathetic tone, aldosterone, fibrosis,
VH, BP
3. Adverse Effects
a. Same as ARB/ACE
4. Contraindications
a. Pregnancy
b. Breast Feeding
c. Aliskiren + diabetes + ARNI
d. Lithium
5. Monitor
a. BUN, SCr, electrolytes, BP
6. Outcomes
a. Hospitalizations (PARADIGM-HF Trial)
b. CV death (PARADIGM-HF Trial)
7. Target Dose
a. Sacubitril/Valsartan 97/102 mg BID
b. ACE/ARB naïve, ≥75 YO, low BP, liver impairment
start at lowest dose 24/26 mg
viii. Digoxin
1. HFrEF, hospitalizations despite optimized doses
2. Positive Inotrope, Negative Chronotrope
3. Negative dromotrope
a. Decrease K -> Decrease Conduction Velocity
4. Increases intracellular Ca & Decreases K
5. Adverse Effects
a. Shortens ST duration
i. Premature ventricular contractions
b. Anorexia, NV
c. Halos around objects, yellow/green color
aberrations, blurred vision
d. Quinidine reduces clearance
6. Monitor
a. BUN, SCr, K, HR, symptoms
7. Outcomes
a. Hospitalizations
b. Symptoms
c. Exercise tolerance
d. Does NOT improve survival
8. Target Dose
a. Digoxin 125-250 mcg QD
b. Elderly, renal, lean body mass, require lower dose
c. Narrow TPI 0.5 to 0.9 ng/mL in blood
ix. Diuretics – Improve symptoms only
1. HFrEF with congestive symptoms
2. Decrease volume -> Decrease Preload
3. Mildly decrease BP, increase HR
4. Monitor
a. BUN, SCr, electrolytes, BP
i. K > 4.0 mEq/L
5. Outcomes
a. Symptoms
i. QOL, exercise tolerance
b. Does NOT improve survival
6. Target Dose
a. Furosemide 20-40-600 mg in divided doses
i. IV:PO = 1:2
b. Bumetanide 0.5-10 mg QD or in divided doses
c. Torsemide 10-20-200 mg QD
d. Metolazone 2.5-10 mg 30 minutes before loop
diuretic
i. For loop diuretic resistance
ii. Inhibits Na reabsorption
e. Weight loss 0.5-1 kg daily
e. Non-Pharm Treatment
i. Na < 2 g/day
ii. Fluids < 2 K/day if fluid overloaded
iii. Manage comorbidities
iv. Weight reduction if overweight
v. Physical Activity as tolerated

IV. Acute Decompensated Heart Failure – ADHF


a. Diuretics if PCWP ≥ 18
i. Improves mortality if given within 1 hour of admission
1. REALITY-AHF Trial
ii. Dose
1. Double TOTAL home oral dose
a. Furosemide 40 mg po = 40 mg IV
i. Furosemide IV:PO = 1:2
b. Bumetanide 1 mg po = 2 mg IV
2. Naïve = Furosemide 40 mg IV
3. IV bolus or continuous infusion
4. Ceiling for Bolus Dose
a. Furosemide 40-80 mg IV
i. Max infusion rate 4 mg/min
ii. Ototoxicity
b. Torsemide 20-40 mg
c. Bumetanide 1-2 mg
d. Ethacrynic Acid 30 mg
i. Used for sulfa allergy
e. Dose more frequently or use continuous infusion
when at ceiling
5. Diuretic Resistance – DOSE Trial
a. Decreased kidney perfusion -> reduced drug
delivery
b. Use higher doses, continuous infusion, second
diuretic, Na/fluid restriction, dopamine (renal
dose), ultrafiltration dialysis
b. Vasodilators if SBP ≥90 mm Hg
i. Warm & Wet, Cold & Wet with MAP >50 and SBP >90
ii. Venous dilators
1. Reduce Preload, PCWP, edema
iii. Arterial Dilators
1. Reduce Afterload, SVR
2. Increase SV, CO
iv. Nitroglycerin
1. Increase cGMP -> vasodilation
a. Venous mostly, arterial at high dose >100
mcg/min
b. Dose
i. 5 mcg/min IV up to 200 mcg/min
ii. T1/2 = 1-4 minutes
v. Nesiritide
1. Recombinant BNP
a. Increase cGMP -> vasodilation -> Reduce Preload,
PCWP, SVR
i. Veins and arteries
vi. Sodium Nitroprusside
1. NO -> Increase cGMP -> vasodilation
a. Veins and arteries
2. Cold & Wet
c. Inotropes if PCWP ≥ 15
d. Fluids if PCWP < 15
e. Ventricular Assist Device – VAD
i. LVAD – Left VAD
1. LV or LA -> Aorta
ii. RVAD – Right VAD
1. RV or RA -> pulmonary artery
iii. BiVAD – Left and Right VAD
iv. Requires anticoagulation

V. Dyslipidemia Pathophysiology
a. Lipids
i. Cholesterol
1. Cell membrane formation
2. Bile Acid precursor
3. Steroid, hormone, Vit D synthesis
4. Sources
a. In vivo synthesis – 80% in liver and intestines
i. Mevalonate production is rate limiting step
1. Catalyzed by HMG-CoA reductase –
statin target
b. Extraction from lipoproteins
c. Diet has modest impact
ii. Triglycerides
1. Glycerol + fatty acids
2. Derived from food
3. Stored energy in adipose
iii. Phospholipids
1. Lipid transport
2. Oxidation of arterial wall lipoproteins
b. Lipoproteins
Lipoprotein Content Metabolism Function
chylomicron 98-99% TG LPL into FFA Transfers TG
Bile Acids and remnants and cholesterol
gut -> liver
VLDL & IDL Mostly TG VLDL + LPL -> LDL Precursor
15-20% of IDL -> LDL
serum
cholesterol
apo B
LDL 60-70% of Liver removes VLDL transport
serum 70% TG and
cholesterol cholesterol
PCSK9 inhibition IDL transports
-> increase LDL cholesterol
metabolism Atherosclerosis
by attaching to
arterial walls by
oxidation
Small, dense
LDL is worse
HDL 20-30% of Removes
serum excess
cholesterol cholesterol
CETP allows
exchange of TG
and cholesterol
LCAT allows
cholesterol
collection
c. Risk Factors
i. Non-modifiable
1. Male ≥45 YO, Female ≥ 55 YO
2. Family history
3. Gender
4. Socioeconomic status
ii. Modifiable
1. Tobacco
2. Stress
3. Diet
4. Physical Activity
5. Obesity
6. HTN
7. Lipid disorders
8. diabetes
d. Pathogenesis
i. Injury to endothelium -> inflammation -> fibrous cap -> plaque
rupture
ii. LDL oxidation triggers inflammation and macrophage
activation
1. Foam Cells – lipid filled macrophages
2. Foam cells accumulate to form fatty streak
iii. Fibrous cap – Protects core of lipids, macrophages, collagen
1. Can rupture to release material
2. Forms clot to block vessel
e. Secondary Causes
i. TC > 200 mg/dL
1. Hypothyroid
2. Liver disease
3. Corticosteroids
4. Protease inhibitors
5. Thiazide diuretics
6. Beta blockers
ii. LDL ≥ 190 mg/dL
1. Usually primary cause (FH, apo B-100 defect)
iii. TG ≥ 150 mg/dL
1. TG >500 mg/dL -> pancreatitis
2. T2DM
3. Obesity
4. Tobacco
5. Alcohol
6. Physical inactivity
7. High carbohydrate intake
8. Corticosteroids
9. Beta blockers
10.Thiazide diuretics
11. Bile acid sequestrant
12. Atypical antipsychotics
iv. HDL < 40 mg/dL
1. Obesity
2. Physical inactivity
3. Tobacco
4. T2DM
5. Beta blockers
6. Anabolic steroids
7. Progestational agents
f. Lab Values
i. TC <200 mg/dL
ii. Non-HDL <130 mg/dL
iii. LDL <100 mg/dL
iv. HDL >40 in men, >50 in women
v. TG <150 mg/dL

VI. Dyslipidemia Therapeutics


a. Lifestyle
i. Diet
1. vegetables, fruits, whole grains, legumes, non-tropical
vegetable oils (more dense, saturated fats due to
warmer climate)
2. Protein: low fat dairy, poultry without skin, fish, nuts
3. Limit red meats, sweet
ii. Physical Activity
1. 3-4 sessions/week of aerobic activity
a. 40 minutes/session
b. Moderate-vigorous intensity
iii. Weight loss
1. 10 lb weight loss increases HDL by 1.6 mg/dL
iv. Alcohol and smoking cessation
b. Lipid Lowering Agents
i. Statins – HMG-CoA Reductase Inhibitor
1. Adverse Effects
a. Myopathy in large muscles
b. LFT Elevations
c. Cognitive impairment
2. Contraindications
a. CYP3A4 inhibitors
i. Simvastatin, lovastatin highest risk
ii. Pravastatin not metabolized by CYP450
b. Gemfibrozil (increase ADR)
c. Pregnancy
d. Lactation
3. Monitoring
a. LFT – Baseline and if abnormal
b. Lipid panel
c. CPK - myopathy
4. Counseling
5. Place in Therapy
a. Outcomes
i. Major coronary events
ii. Mortality
iii. Pleiotropic effects
1. Vasodilation, plaque stability
2. Decrease inflammation, lipoprotein
oxidation, coagulation
b. Dose
i. High – LDL-C Reduction >50%
1. Rosuvastatin 20-40 mg QD
2. Atorvastatin 40-80 mg QD
ii. Moderate – LDL-C Reduction 30-50%
iii. Low – LDL-C Reduction <30%
iv. Duration
1. Long: atorvastatin, rosuvastatin,
pitavastatin
2. Short: lovastatin, pravastatin,
simvastatin, Fluvastatin
a. Dose PM
ii. Ezetemibe
1. Adverse Effects
a. Myopathy (+ statins)
b. Diarrhea
c. URI
d. Cough
2. Contraindications
a. Moderate-severe liver impairment
3. Monitoring: see statins
4. Outcomes
a. CV Outcomes - IMPROVE-IT Trial
iii. PCSK9 Inhibitors
1. Agents
a. Evolocumab (Repatha)
b. Alirocumab (Praluent)
c. Approved for FH and clinical ASCVD requiring LDL-
C reduction
2. Adverse Effects
3. Contraindications
4. Monitoring
a. Lipid panel
b. LFTs
5. Counseling
6. Place in Therapy
a. Outcomes
i. CV Outcomes
1. ODYSSEY, FOURIER Trials
iv. Bile Acid Sequestrant (BAS)
1. Agents
a. Colesevelam
b. Colestipol
c. Cholestyramine
2. Adverse Effects
a. Increase TG
b. GI Upset
3. Contraindications
a. TG > 400 mg/dL
b. Chronic constipation
4. Monitoring
5. Counseling
a. Other drugs 1 hour before or 4 hours after BAS
i. Decreased absorption
v. Fibric Acid
1. Agents
a. Fenofibrate
i. ER did not meet primary or secondary CV
outcomes
ii. Renal dosing
iii. Once daily with or without food
b. Gemfibrozil
i. Myopathy
ii. Twice daily with meals
2. Monitor
a. Lipid, LFT, CPK
vi. Omega-3 Fatty Acids
1. Agents
a. Omega-3 acid ethyl esters
b. Icosapent – EPA Only
i. CV Benefit – ASCEND Trial
2. Adverse Effects
a. Fish burps
i. Store in freezer
ii. Avoid hot liquids
iii. Take with meals
iv. Use EC
b. Diarrhea
vii. Niacin (nicotinic acid)
1. Adverse Effects
a. Flushing
i. Take with food
ii. ASA 325 Pre-medicate
iii. Avoid hot liquids, alcohol
b. Pruritis
c. Myopathy
i. LFT Elevations
d. Hyperuricemia
e. Hyperglycemia
i. Caution: DM
2. Monitoring
a. Lipid
b. LFT
c. CPK
d. Glu/A1C
e. Uric Acid if History of Gout
viii. Summary
1. LDL-C Reduction
a. Statins
b. Ezetemibe
c. PCSK9 Inhibitors
d. BAS
2. TG Reduction
a. Fibrates
b. Omega-3
c. Niacin
c. Guidelines
i. ASCVD 10 Year Risk
1. % Risk of CHD Death, MI, Stroke
2. Baseline lipid panel off statin therapy
ii. Patient Groups
1. Secondary Prevention of Clinical ASCVD
2. Primary Hypercholesterolemia, LDL ≥190 mg/dL
3. Diabetes in Adults
4. Risk Based Need for Primary Prevention

Вам также может понравиться